Interim Results on Fedratinib - ASH 2013 - Claire Harrison, DM, FRCP
From ASH 2013, Claire Harrison, DM, FRCP, FRCPath, discusses the JAK2 inhibitor Fedratinib and the abstract 661 "Efficacy and Safety Of Fedratinib In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera MF, Or Post-Essential Thrombocythemia MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2)"
Recent Video
Most Popular
Specialties :                    Search : is a member of the Oncology.TV family of oncology medical education websites. offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).